 | Up a level |
Concordet, D and Gandia, P and Montastruc, J-L and Bousquet-Mélou, A and Lees, P and Ferran, A A and Toutain, P-L (2019) Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One? Clinical Pharmacokinetics, 59. pp. 1-5.
Concordet, D and Gandia, P and Montastruc, J L and Bousquet-Mélou, A and Lees, P and Ferran, A and Toutain, P L (2019) Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?". Clinical Pharmacokinetics.
Concordet, D and Gandia, P and Montastruc, J L and Bousquet-Mélou, A and Lees, P and Ferran, A and Toutain, P L (2019) Levothyrox® new and old formulations: are they switchable for millions of patients? Clinical Pharmacokinetics.